Publications
78
Citations
3,943
Est. group size
~11
Recurring co-author estimate
Active years
44
Publishing since 1983
Typically publishes in teams of ~20 · 0% small-team papers (≤3 authors) · across 9 venues
- A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (Mm): Primary Analysis. Amarc 19-02 Belacard Study
Clinical Lymphoma Myeloma & Leukemia · 2025
- Tobacco smoking and nicotine vaping in persons with first episode psychosis
Schizophrenia Research · 2024
- Mammalian Glycosylation Patterns Protect Citrullinated Chemokine MCP-1/CCL2 from Partial Degradation
International Journal of Molecular Sciences · 2023
- P946: A PHASE I/II SINGLE ARM STUDY OF BELANTAMAB MAFODOTIN, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: AMARC 19-02 BELACARD STUDY.
HemaSphere · 2022
- Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission
Molecular Psychiatry · 2021
- Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
The Lancet Oncology · 2020
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Journal of Clinical Oncology · 2020
- INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Hematological Oncology · 2019
- Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
Clinical Lymphoma Myeloma & Leukemia · 2019
- Acalabrutinib versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL: The Randomised, Controlled, Phase 3 ASCEND Trial
SSRN Electronic Journal · 2019
- Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Clinical Lymphoma Myeloma & Leukemia · 2018
- Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia
Journal of Clinical Oncology · 2017
- Experimental sadness induces relevant interactions between central endogenous opioid activation and plasma IL-18 concentrations in depressed volunteers
Molecular Psychiatry · 2016
- Arthritis Research & Therapy×4
- JCI Insight×3
- Arthritis & Rheumatology×3
- Clinical Lymphoma Myeloma & Leukemia×3
- bioRxiv (Cold Spring Harbor Laboratory)×3
- M. Asif Amin
Medicine · University of Michigan
- Cheng‐Hsun Lu
Medicine · University of Michigan
- Jeffrey H. Ruth
Medicine · University of Michigan
- Vincent A. Laufer
Medicine · University of Michigan
- Beatriz Y. Hanaoka
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile